Introduction
Methods
Criteria of inclusion and exclusion
Data acquisition and outcome measures
Statistical analysis
Results
Median (range) | |
Age (years) | 67 (30–88) |
BMI (kg/m2) | 24.6 (15–39) |
n (%) | |
Gender (female/male) | 131/120 (52%/48%) |
Smokers | 53 (21%) |
Alcohol abuse | 28 (11%) |
ASA Score [12] | |
I | 13 (5%) |
II | 152 (61%) |
III | 81 (33%) |
IV | 3 (1%) |
Common comorbidities | |
Hypertension | 133 (54%) |
Post pancreatitis | 125 (50%) |
Hepatic disease | 100 (40%) |
Coronary heart disease | 43 (17%) |
Pulmonary disease | 33 (13%) |
Renal insufficiency | 30 (12%) |
Diabetes | 28 (11%) |
Localization of tumor | |
Head | 209 (83%) |
Body | 16 (7%) |
Tail | 26 (10%) |
Type of surgery | |
Pancreatoduodenectomy | 190 (76%) |
Distal pancreatectomy | 29 (13%) |
Total pancreatectomy | 32 (11%) |
Complications | |
Intraoperative complication | 18 (7%) |
Postoperative complication | 143 (57%) |
Operative revision | 38 (15%) |
median (range) | |
Hospital stay (days) | |
Overall | 18 (7–63) |
Intensive care unit | 5 (1–32) |
Drain remove (days) | 7 (0–62) |
G | T | N | M | Pn | L | V | R | ||
---|---|---|---|---|---|---|---|---|---|
0 | n | 68 | 242 | 44 | 60 | 163 | 181 | ||
% | 27 | 96 | 18 | 24 | 65 | 72 | |||
1 | n | 7 | 6 | 183 | 8 | 157 | 132 | 39 | 67 |
% | 3 | 3 | 73 | 3 | 63 | 53 | 16 | 27 | |
2 | n | 158 | 16 | 2 | 3 | ||||
% | 63 | 6 | 1 | 1 | |||||
3 | n | 83 | 218 | ||||||
% | 33 | 87 | |||||||
4 | n | 3 | 9 | ||||||
% | 1 | 4 | |||||||
Overall | 251 | 251 | 251 | 250 | 201 | 192 | 204 | 251 |
Chemotherapy treatment
Subgroup analysis of long-term survivors (> 5 years)
CTx | noCTx | |
---|---|---|
Median (range) | Median (range) | |
Age (years) | 69 (65–70) | 57 (30–84) |
BMI (kg/m2) | 23.4 (23–32) | 24.5 (23–25) |
n (%) | ||
Gender (female/male) | 4/0 (100/0%) | 3/1 (75/25%) |
Smokers | 0 (0%) | 1 (25%) |
Alcohol abuse | 0 (0%) | 0 (0%) |
ASA Score [12] | ||
I | 1 (25%) | 0 (0%) |
II | 2 (50%) | 2 (50%) |
III | 1 (25%) | 2 (50%) |
IV | 0 (0%) | 0 (0%) |
Common comorbidities | ||
Hypertension | 1 (25%) | 3 (75%) |
Post pancreatitis | 2 (50%) | 2 (50%) |
Hepatic disease | 1 (25%) | 0 (0%) |
Coronary heart disease | 0 (0%) | 0 (0%) |
Pulmonary disease | 0 (0%) | 0 (0%) |
Renal insufficiency | 0 (0%) | 1 (25%) |
Diabetes | 1 (25%) | 0 (0%) |
Localization of tumor | ||
Head | 3 (75%) | 4 (100%) |
Body | 1 (25%) | 0 (0%) |
Tail | 0 (0%) | 0 (0%) |
Grading of tumor | ||
G2 | 3 (75%) | 4 (100%) |
G3 | 0 (0%) | 0 (0%) |
G4 | 1 (25%) | 0 (0%) |
Invasion of lymph nodes (N) | ||
N0 | 2 (50%) | 2 (50%) |
N1 | 2 (50%) | 2 (50%) |
Type of surgery | ||
Pancreatoduodenectomy | 3 (75%) | 4 (100%) |
Distal pancreatectomy | 1 (25%) | 0 (0%) |
Total pancreatectomy | 0 (0%) | 0 (0%) |
Complications | ||
Intraoperative complication | 0 (0%) | 0 (0%) |
Postoperative complication | 3 (75%) | 2 (50%) |
Operative revision | 0 (0%) | 0 (0%) |
Median (range) | Median (range) | |
Hospital stay (days) | ||
Overall | 17 (14–45) | 21 (16–31) |
Intensive care unit | 5 (3–6) | 7 (4–7) |
Drain remove (days) | 6 (3–45) | 7 (5–8) |
Concordance of tumor marker and survival
Recurrence and survival
Multivariate risk analysis (see Table 4)
Survival [months] | CI [months] | p | ||
---|---|---|---|---|
Gender | Male | 19.6 | 16.2–23.1 | 0.705 |
Female | 21.9 | 16.8–27.0 | ||
Age [years] | < 63 | 22.8 | 14.9–30.7 | 0.085 |
< 72 | 22.5 | 17.7–27.4 | ||
≥ 72 | 17.6 | 13.7–21.4 | ||
BMI [kg/m2] | > 24,6 | 18.7 | 16.1–21.3 | 0.903 |
≥ 24,6 | 21.9 | 18.2–25.6 | ||
Weight loss [kg] (preoperatively) | < 5 | 19.0 | 14.5–23.5 | 0.878 |
≥ 5 | 21.2 | 17.1–25.3 | ||
Comorbidities | Yes | 20.7 | 17.5–24.0 | 0.464 |
No | 19.5 | 7.9–31.2 | ||
Pancreatitis (preoperatively) | Yes | 18.5 | 14.3–22.7 | 0.395 |
No | 22.5 | 18.1–27.0 | ||
Diabetes (postoperatively) | Yes | 21.2 | 15.8–26.5 | 0.565 |
No | 20.3 | 16.2–24.5 | ||
ASA [12] | I | 20.4 | 11.1–29.6 | 0.732 |
II | 21.5 | 17.8–25.2 | ||
III | 19.7 | 13.5–25.3 | ||
IV | 12.1 | 3.1–21.1 | ||
Alcohol | Yes | 19.7 | 2.7–23.5 | 0.585 |
No | 17.2 | 17.2–23.5 | ||
Nicotine | Yes | 22.8 | 16.3–29.2 | 0.661 |
No | 19.7 | 16.2–23.2 | ||
Diagnosis to OP [days] | < 23 | 20.4 | 16.5–24.2 | 0.817 |
≥ 23 | 20.4 | 15.6–25.1 | ||
Duration of OP [min] | < 400 | 19.6 | 16.5–22.7 | 0.505 |
≥ 400 | 21.9 | 16.8–27.1 | ||
ICU stay [days] | < 5 | 19.4 | 13.7–25.1 | 0.837 |
≥ 5 | 20.4 | 14.6–26.1 | ||
Hospital stay [days] | < 18 | 20.8 | 16.2–25.4 | 0.147 |
≥ 18 | 20.4 | 16.4–24.3 | ||
Drain removal [days] | < 7 | 19.6 | 15.6–23.5 | 0.075 |
≥ 7 | 20.4 | 16.1–24.6 | ||
Complications (intraoperatively) | Yes | 17.4 | 14.2–20.6 | 0.385 |
No | 21.2 | 18.2–24.2 | ||
Complications (postoperatively) | Yes | 21.9 | 15.1–28.7 | 0.994 |
No | 20.4 | 18.2–22.5 | ||
Blood transfusion (intraoperatively) | Yes | 13.4 | 3.0–23.8 | 0.118 |
No | 20.8 | 17.6–24.1 | ||
Re-operation | Yes | 15.1 | 10.1–20.2 | 0.323 |
No | 22.5 | 18.5–24.6 | ||
Adjuvant chemotherapy | Yes | 25.6 | 21.8–29.4 | 0.001 |
No | 14.3 | 11.0–17.7 | ||
Abandonment of chemotherapy | Yes | 27.7 | 22.6–32.8 | 0.009 |
No | 19.7 | 11.3–281 | ||
Cycles | 1–3 | 14 | 0.2–11.7 | 0.026 |
4–5 | 26.3 | 3–20.4 | ||
6 | 27.7 | 1.7–24.4 | ||
Rehabilitation | Yes | 21.5 | 18.3–24.8 | 0.159 |
No | 15.1 | 8.2–22.1 | ||
OP to rehabilitation [days] | < 21 | 23.6 | 14.9–32.3 | 0.419 |
≥ 21 | 18.5 | 16.5–20.5 | ||
Tumor localization | Caput | 20.4 | 17.2–23.5 | 0.515 |
Corpus | 19.4 | 6.2–40.6 | ||
Caudae | 22.6 | 11.3–33.8 | ||
Tumor size | T1 | 38.3 | 19.9–56.6 | 0.212 |
T2 | 20.7 | 15.7–25.8 | ||
T3 | 19.7 | 16.1–23.3 | ||
T4 | 10.1 | 0–21.9 | ||
Tumor grade | G1/G2 | 21.6 | 16.7–26.4 | 0.019 |
G3/G4 | 15.2 | 7.3–23.1 | ||
Lymph node invasion | N0 | 30.6 | 24.2–37.6 | < 0.001 |
N1 | 17.3 | 1.8–13.8 | ||
Lymph vessel invasion | L0 | 26.6 | 12.3–41.0 | 0.014 |
L1 | 17.4 | 13.3–21.6 | ||
Vein invasion | V0 | 22.6 | 18.5–26.6 | 0.016 |
V1 | 14.4 | 11.5–17.4 | ||
V2 | 10.3 | n/c | ||
Perineural invasion | Pn0 | 21.6 | 15.3–27.8 | 0.242 |
Pn1 | 19.6 | 14.9–24.3 | ||
Distant metastases | M0 | 20.8 | 17.7–24.0 | 0.012 |
M1 | 6.6 | 1.4–17.4 | ||
Resection | R0 | 24.3 | 19.6–29.2 | < 0.001 |
R1 | 13.3 | 10.7–15.9 | ||
R2 | 14.4 | 17.3–23.4 | ||
CA 19.9 [U/mL] (time of diagnosis) | < 37 | 23.6 | 21.3–33.4 | 0.071 |
< 100 | 27.6 | 24.3–41.0 | ||
< 500 | 18.0 | 18.0–26.3 | ||
< 1000 | 14.1 | 13.3–23.5 | ||
≥ 1000 | 10.4 | 9.3–27.5 | ||
CA 19.9 [U/mL] (postoperatively) | < 37 | 26.4 | 25.3–32.8 | 0.031 |
< 100 | 15.9 | 12.2–28.4 | ||
< 500 | 14.4 | 12.3–22.5 | ||
< 1000 | 13.0 | − 11.3 to 44.2 | ||
≥ 1000 | 9.9 | 7.2–18.3 | ||
CA 19.9 [U/mL] (time of recurrence) | < 37 | 25.2 | 21.8–35.4 | 0.193 |
< 100 | 22.5 | 19.0–29.3 | ||
< 500 | 23.7 | 20.8–31.1 | ||
< 1000 | 16.3 | 14.9–25.0 | ||
≥ 1000 | 10.3 | 10.1–18.0 |